{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:41:46Z","timestamp":1771476106441,"version":"3.50.1"},"reference-count":125,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF)","award":["2019M3E5D5065771"],"award-info":[{"award-number":["2019M3E5D5065771"]}]},{"name":"National Research Foundation of Korea (NRF)","award":["2020M3A9C8017745"],"award-info":[{"award-number":["2020M3A9C8017745"]}]},{"name":"Ministry of Science and ICT","award":["2019M3E5D5065771"],"award-info":[{"award-number":["2019M3E5D5065771"]}]},{"name":"Ministry of Science and ICT","award":["2020M3A9C8017745"],"award-info":[{"award-number":["2020M3A9C8017745"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Viral infections can be fatal and consequently, they are a serious threat to human health. Therefore, the development of vaccines and appropriate antiviral therapeutic agents is essential. Depending on the virus, it can cause an acute or a chronic infection. The characteristics of viruses can act as inhibiting factors for the development of appropriate treatment methods. Genome editing technology, including the use of clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) proteins, zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs), is a technology that can directly target and modify genomic sequences in almost all eukaryotic cells. The development of this technology has greatly expanded its applicability in life science research and gene therapy development. Research on the use of this technology to develop therapeutics for viral diseases is being conducted for various purposes, such as eliminating latent infections or providing resistance to new infections. In this review, we will look at the current status of the development of viral therapeutic agents using genome editing technology and discuss how this technology can be used as a new treatment approach for viral diseases.<\/jats:p>","DOI":"10.3390\/ijms23105399","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T21:46:53Z","timestamp":1652392013000},"page":"5399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Application of Genome Editing Technologies in Viral Diseases"],"prefix":"10.3390","volume":"23","author":[{"given":"Tae Hyeong","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Dankook University, Cheonan 31116, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Bioconvergence Engineering, Research Institute of Advanced Omics, Dankook University, Yongin 16890, Korea"},{"name":"R&D Center, Rznomics Inc., Seongnam 13486, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kim, T.H., and Lee, S.W. (2021). Aptamers for Anti-Viral Therapeutics and Diagnostics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084168"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"716344","DOI":"10.3389\/fcell.2021.716344","article-title":"Genome Editing Technologies as Cellular Defense Against Viral Pathogens","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nbt1125","article-title":"Gene targeting using zinc finger nucleases","volume":"23","author":"Porteus","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10570","DOI":"10.1073\/pnas.95.18.10570","article-title":"FokI dimerization is required for DNA cleavage","volume":"95","author":"Bitinaite","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.1078395","article-title":"Chimeric nucleases stimulate gene targeting in human cells","volume":"300","author":"Porteus","year":"2003","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ymthe.2005.06.094","article-title":"Custom zinc-finger nucleases for use in human cells","volume":"12","author":"Alwin","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nbt1317","article-title":"Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases","volume":"25","author":"Szczepek","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1074\/jbc.R113.488247","article-title":"A cut above the rest: Targeted genome editing technologies in human pluripotent stem cells","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pbi.2010.04.010","article-title":"TAL effectors: Finding plant genes for disease and defense","volume":"13","author":"Bogdanove","year":"2010","journal-title":"Curr. Opin. Plant. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gkr218","article-title":"Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting","volume":"39","author":"Cermak","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nbt.2170","article-title":"FLASH assembly of TALENs for high-throughput genome editing","volume":"30","author":"Reyon","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nbt.2460","article-title":"A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes","volume":"31","author":"Schmidt","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1099\/mic.0.28048-0","article-title":"Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin","volume":"151","author":"Bolotin","year":"2005","journal-title":"Microbiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/mic.0.27437-0","article-title":"CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies","volume":"151","author":"Pourcel","year":"2005","journal-title":"Microbiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of CRISPR-Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/bs.pmbts.2020.12.012","article-title":"History, evolution and classification of CRISPR-Cas associated systems","volume":"179","author":"Agarwal","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nbt.2508","article-title":"RNA-guided editing of bacterial genomes using CRISPR-Cas systems","volume":"31","author":"Jiang","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JB.01412-07","article-title":"Phage response to CRISPR-encoded resistance in Streptococcus thermophilus","volume":"190","author":"Deveau","year":"2008","journal-title":"J. Bacteriol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.clindermatol.2013.08.007","article-title":"HPV-associated diseases","volume":"32","author":"Ljubojevic","year":"2014","journal-title":"Clin. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53","volume":"248","author":"Werness","year":"1990","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines\u2014A review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41598-017-05696-0","article-title":"TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells","volume":"7","author":"Shankar","year":"2017","journal-title":"Sci Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"612823","DOI":"10.1155\/2014\/612823","article-title":"Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells","volume":"2014","author":"Hu","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_34","first-page":"1700540","article-title":"HPV Oncogene Manipulation Using Nonvirally Delivered CRISPR\/Cas9 or Natronobacterium gregoryi Argonaute","volume":"5","author":"Lao","year":"2018","journal-title":"Adv. Sci. (Weinh.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2021.07.005","article-title":"CRISPR\/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells","volume":"562","author":"Inturi","year":"2021","journal-title":"Virology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Basukala, O., Mittal, S., Massimi, P., Bestagno, M., and Banks, L. (2019). The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour-derived cells. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007769"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fan, W., Yu, M., Wang, X., Xie, W., Tian, R., Cui, Z., Jin, Z., Huang, Z., Das, B.C., and Severinov, K. (2021). Non-homologous dsODN increases the mutagenic effects of CRISPR-Cas9 to disrupt oncogene E7 in HPV positive cells. Cancer Gene Ther.","DOI":"10.1038\/s41417-021-00355-z"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2021.12.011","article-title":"Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6\/E7 genes in cervical cancer cells","volume":"24","author":"Tian","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.ymthe.2019.08.012","article-title":"Systemic Delivery of CRISPR\/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors","volume":"27","author":"Jubair","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jubair, L., Lam, A.K., Fallaha, S., and McMillan, N.A.J. (2021). CRISPR\/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0223288"},{"key":"ref_41","first-page":"2197","article-title":"CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6","volume":"17","author":"Yoshiba","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/hum.2019.312","article-title":"Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats\/Cas9 Delivered by pH-Sensitive Cationic Liposomes","volume":"31","author":"Zhen","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41598-022-06025-w","article-title":"Antiproliferative effects of AAV-delivered CRISPR\/Cas9-based degradation of the HPV18-E6 gene in HeLa cells","volume":"12","author":"Noroozi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.tim.2018.09.009","article-title":"SAMHD1 Suppression of Antiviral Immune Responses","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00448","DOI":"10.1128\/mSphere.00448-19","article-title":"SAMHD1 Regulates Human Papillomavirus 16-Induced Cell Proliferation and Viral Replication during Differentiation of Keratinocytes","volume":"4","author":"James","year":"2019","journal-title":"mSphere"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/187152611795768088","article-title":"Herpes simplex encephalitis: From virus to therapy","volume":"11","author":"Rozenberg","year":"2011","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23146","DOI":"10.1038\/srep23146","article-title":"Inhibition of HSV-1 Replication by Gene Editing Strategy","volume":"6","author":"Roehm","year":"2016","journal-title":"Sci Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., Kruse, E.M., Hooykaas, M.J., Bruggeling, C.E., Schurch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1134\/S0026893319010059","article-title":"A Plasmid-Expressed CRISPR\/Cas9 System Suppresses Replication of HSV Type I in a Vero Cell Culture","volume":"53","author":"Karpov","year":"2019","journal-title":"Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.omtm.2020.05.011","article-title":"Single AAV-Mediated CRISPR-SaCas9 Inhibits HSV-1 Replication by Editing ICP4 in Trigeminal Ganglion Neurons","volume":"18","author":"Chen","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5603\/FHC.a2020.0020","article-title":"A knockdown of the herpes simplex virus type-1 gene in all-in-one CRISPR vectors","volume":"58","author":"Khodadad","year":"2020","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.11.2.8","article-title":"Targeting NECTIN-1 Based on CRISPR\/Cas9 System Attenuated the Herpes Simplex Virus Infection in Human Corneal Epithelial Cells In Vitro","volume":"11","author":"Li","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/rmv.456","article-title":"Reactivation of Epstein-Barr virus from latency","volume":"15","author":"Amon","year":"2005","journal-title":"Rev. Med. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.humpath.2018.05.020","article-title":"Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update","volume":"79","author":"Rezk","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1099\/jgv.0.000012","article-title":"CRISPR\/Cas9-mediated genome editing of Epstein\u2013Barr virus in human cells","volume":"96","author":"Yuen","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_56","first-page":"3687","article-title":"Nasopharyngeal carcinoma: A review of current updates","volume":"15","author":"Wu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/jvi.69.2.675-683.1995","article-title":"The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues","volume":"69","author":"Kaye","year":"1995","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13027-019-0246-5","article-title":"CRISPR\/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth","volume":"14","author":"Huo","year":"2019","journal-title":"Infect. Agent Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/boc.201900085","article-title":"Characterisation of endogenous Claudin-1 expression, motility and susceptibility to hepatitis C virus in CRISPR knock-in cells","volume":"112","author":"Clement","year":"2020","journal-title":"Biol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111239","DOI":"10.1016\/j.biopha.2021.111239","article-title":"CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy","volume":"136","author":"Ashraf","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","article-title":"Programmable Inhibition and Detection of RNA Viruses Using Cas13","volume":"76","author":"Freije","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Malone, R.W., Homan, J., Callahan, M.V., Glasspool-Malone, J., Damodaran, L., Schneider Ade, B., Zimler, R., Talton, J., Cobb, R.R., and Ruzic, I. (2016). Zika Virus: Medical Countermeasure Development Challenges. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004530"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika Virus and Birth Defects--Reviewing the Evidence for Causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.1074\/jbc.RA119.009113","article-title":"Double-stranded RNA deaminase ADAR1 promotes the Zika virus replication by inhibiting the activation of protein kinase PKR","volume":"294","author":"Zhou","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1021\/acs.jmedchem.9b00775","article-title":"Drugs for the Treatment of Zika Virus Infection","volume":"63","author":"Bernatchez","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3389\/fmicb.2020.01745","article-title":"ANKS4B Restricts Replication of Zika Virus by Downregulating the Autophagy","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkac016","article-title":"Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses","volume":"50","author":"Lin","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000197314","article-title":"Influenza Virus","volume":"36","year":"2009","journal-title":"Transfus. Med. Hemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.51.1.407","article-title":"Global epidemiology of influenza: Past and present","volume":"51","author":"Cox","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e00201","DOI":"10.1128\/mBio.00201-12","article-title":"Reconstruction of the 1918 influenza virus: Unexpected rewards from the past","volume":"3","author":"Taubenberger","year":"2012","journal-title":"mBio"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","article-title":"Emergence and pandemic potential of swine-origin H1N1 influenza virus","volume":"459","author":"Neumann","year":"2009","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.chom.2015.02.019","article-title":"Influenza surveillance: 2014-2015 H1N1 \u201cswine\u201d-derived influenza viruses from India","volume":"17","author":"Tharakaraman","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1126\/science.8493571","article-title":"How does HIV cause AIDS","volume":"260","author":"Weiss","year":"1993","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.imlet.2004.11.026","article-title":"Newly identified host factors modulate HIV replication","volume":"97","author":"Zheng","year":"2005","journal-title":"Immunol. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e144486","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1038\/mtna.2014.52","article-title":"CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice","volume":"3","author":"Yi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/mt.2011.310","article-title":"Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment","volume":"20","author":"Yuan","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.1093\/nar\/gkt571","article-title":"Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells","volume":"41","author":"Qu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtn.2018.04.014","article-title":"Zinc-Finger Nucleases Induced by HIV-1 Tat Excise HIV-1 from the Host Genome in Infected and Latently Infected Cells","volume":"12","author":"Ji","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/QAI.0000000000001190","article-title":"TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus","volume":"74","author":"Shi","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_91","first-page":"243","article-title":"TALENs-mediated homozygous CCR5Delta32 mutations endow CD4+ U87 cells with resistance against HIV1 infection","volume":"17","author":"Yu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2000023","DOI":"10.1002\/biot.202000023","article-title":"Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection","volume":"16","author":"Romito","year":"2021","journal-title":"Biotechnol. J."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ebina, H., Kanemura, Y., Misawa, N., Sakuma, T., Kobayashi, T., Yamamoto, T., and Koyanagi, Y. (2015). A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120047"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Strong, C.L., Guerra, H.P., Mathew, K.R., Roy, N., Simpson, L.R., and Schiller, M.R. (2015). Damaging the Integrated HIV Proviral DNA with TALENs. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125652"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wang, W., Ye, C., Liu, J., Zhang, D., Kimata, J.T., and Zhou, P. (2014). CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115987"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem\/Progenitor Cells Confers HIV-1 Resistance In Vivo","volume":"25","author":"Xu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12977-019-0477-y","article-title":"CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4(+) T cells and hematopoietic stem\/progenitor cells promotes HIV-1 resistance and CD4(+) T cell enrichment in humanized mice","volume":"16","author":"Xiao","year":"2019","journal-title":"Retrovirology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13578-020-00444-w","article-title":"Genome editing of CCR5 by AsCpf1 renders CD4(+)T cells resistance to HIV-1 infection","volume":"10","author":"Liu","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12977-017-0375-0","article-title":"Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection","volume":"14","author":"Wang","year":"2017","journal-title":"Retrovirology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1038\/s41598-018-26894-4","article-title":"HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies","volume":"8","author":"Liu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13578-017-0174-2","article-title":"Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection","volume":"7","author":"Liu","year":"2017","journal-title":"Cell Biosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2017.032","article-title":"Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR\/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection","volume":"29","author":"Yu","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1073\/pnas.1405186111","article-title":"RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection","volume":"111","author":"Hu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"22555","DOI":"10.1038\/srep22555","article-title":"Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR\/Cas9 Gene Editing","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7784","DOI":"10.1038\/s41598-018-26190-1","article-title":"CRISPR\/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures","volume":"8","author":"Ophinni","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.omtn.2020.07.016","article-title":"Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-kappaB Binding Sites","volume":"21","author":"Chung","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.celrep.2016.11.057","article-title":"A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures","volume":"17","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"41968","DOI":"10.1038\/srep41968","article-title":"A combinational CRISPR\/Cas9 gene-editing approach can halt HIV replication and prevent viral escape","volume":"7","author":"Lebbink","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","article-title":"In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models","volume":"25","author":"Yin","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e01486","DOI":"10.1128\/AAC.01486-17","article-title":"Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Nguyen, H., Wilson, H., Jayakumar, S., Kulkarni, V., and Kulkarni, S. (2021). Efficient Inhibition of HIV Using CRISPR\/Cas13d Nuclease System. Viruses, 13.","DOI":"10.1101\/2021.07.21.453273"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"665184","DOI":"10.3389\/fmicb.2021.665184","article-title":"Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR\/SaCas9 Expressed from Liver-Specific Promoters","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1038\/s41598-017-05905-w","article-title":"Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9","volume":"7","author":"Kurihara","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent Inactivation of HBV Genomes by CRISPR\/Cas9-Mediated Non-cleavage Base Editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/ijc.29626","article-title":"CRISPR-Cas9 systems: Versatile cancer modelling platforms and promising therapeutic strategies","volume":"138","author":"Wen","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.tibtech.2019.01.009","article-title":"Improving CRISPR Genome Editing by Engineering Guide RNAs","volume":"37","author":"Moon","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.2673","article-title":"High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity","volume":"31","author":"Pattanayak","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.aad6778","article-title":"GENETIC TECHNOLOGY REGULATION. Editing policy to fit the genome?","volume":"351","author":"Isasi","year":"2016","journal-title":"Science"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:45Z","timestamp":1760137785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":125,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105399"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105399","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}